Clinical Trials Browser

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT07017673 2025-10-06

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Phase 2 Recruiting

34 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06245889 2025-09-23

NeoADAPT

Phase 2 Recruiting

30 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04138719 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Phase 2 Recruiting

520 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04159142 2025-09-11

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

Phase 2 Recruiting

414 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06365788 2025-09-04

ABBICAR

Phase 2 Recruiting

53 enrolled

Breast

Bulbo-Spinal Atrophy, X-Linked, Triple Negative Breast Neoplasms

NCT05582538 2025-08-24

ATRiBRAVE

Phase 2 Recruiting

37 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Phase 2 Recruiting

40 enrolled

Breast

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT03740893 2025-08-11

PHOENIX

Phase 2 Recruiting

119 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07108309 2025-08-07

AREAL

Phase 2 Recruiting

124 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07104266 2025-08-05

Triple Negative Breast Cancer and Celecoxib. Pilot Study

Phase 2 Recruiting

30 enrolled

Breast

Triple Negative Breast Neoplasms

NCT06176261 2025-07-30

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Phase 2 Recruiting

58 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06358573 2025-07-23

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Phase 2 Recruiting

54 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

I-SPY

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

NEOTRIO-2

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

PREDICT-RD

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

PRISM-TNBC

PRELUDE

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

TARMAC

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer

Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.

Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)

NOGA

AZALEA

JS207 Combination Therapy in Triple-negative Breast Cancer

Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer

Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC

Renaissance

A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.

DIAMOND

CAPPA

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM

NeoCARD

NeoSTAR

NeoTRACT

AGADIR

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

NeoADAPT

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced Triple-negative Breast Cancer

ABBICAR

ATRiBRAVE

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

PHOENIX

AREAL

Triple Negative Breast Cancer and Celecoxib. Pilot Study

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK